| 항목 | 2024-06 | 2024-09 | 2024-12 | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.30B | $11.44B | $45.04B | $12.73B | $15.56B | $17.60B | $65.18B | $19.80B |
| Net Income | $2.97B | $970.30M | $10.59B | $2.76B | $5.66B | $5.58B | $20.64B | $7.40B |
| EPS (Diluted) | $3.28 | $1.07 | $11.71 | $3.06 | $6.29 | $6.21 | $22.95 | $8.26 |
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocyti...
🔗 emfls.github.io 다른 콘텐츠 보기
2026년 8월 11일에 재검토했으며 실시간 시세나 투자 권유가 아닙니다. 수익을 보장하지 않고 원금 손실이 가능하므로 공시 원문과 최신 재무자료를 직접 확인하고 필요하면 인가된 전문가와 상담하세요.